Akebia Therapeutics, Inc.
Prolyl hydroxylase inhibitors and methods of use

Abstract:

The present disclosure relates to HIF-1.alpha. prolyl hydroxylase inhibitors, compositions which comprise the HIF-1.alpha. prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.